Mereo Investors Face Lead‑Plaintiff Deadline in Securities Suit Over Setrusumab Trials

Overview

• Plaintiff firms are urging purchasers of Mereo American Depositary Shares during June 5, 2023 to December 26, 2025 to seek lead‑plaintiff status by the April 6, 2026 cutoff.
• The filed class action alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b‑5.
• According to the complaint, Mereo made upbeat statements about its Phase 3 ORBIT and COSMIC studies for setrusumab while concealing adverse facts.
• The suit says neither study met its main goal of lowering the annualized clinical fracture rate versus placebo or bisphosphonate control groups, which it claims left investors with losses after the disclosures.
• No class is certified yet, so investors are not represented unless they retain counsel, and law firms including Rosen and Schall are competing to recruit and lead the case on a contingency basis.